Myocardial InfarctionNorExNCT04617639
The Norwegian Trial of Physical Exercise After Myocardial Infarction
A study testing Physical exercise and Observation group in people with Myocardial Infarction, run by Norwegian University of Science and Technology at 1 site in Norway.
Trial summary
Myocardial infarction (MI) remains the main cause of death in Europe with about 2 million deaths annually. According to WHO, 30 % of deaths caused by MI could be prevented if the populations adhere to official guidelines for physical activity. Read more about this study
- Who is it for?
- Ages 18 to 79 years
- Conditions the study is for
- Myocardial Infarction
- What is being tested?
- Physical exercise and Observation group
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 9,513 participants
- Where
- 1 siteNorway
- Study dates
- 29 Sep 2020to 31 Dec 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 79 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Hospitalized in a Norwegian hospital with an acute myocardial infarction (Type I) during 2013-2022. Patients are included minimum 3 months after hospitalization when they are in a stable clinical condition.
- Norwegian national identification number
- Able to communicate in Norwegian or other Scandinavian language
- Being able to be physically active according to study protocol, as determined by study personnel.
- Signed informed consent.
Who cannot join
- Persons who already participate in physical activity at a similar or higher level than what is prescribed for the intervention group, as determined by study personnel.
- Participating or plans to participate in endurance sport competitions.
- Expected to emigrate during the study
- Cognitive impairment/dementia.
- Alcohol or drug abuse, or serious psychiatric disease.
- Known cardiac disease that may represent a contraindication for moderate or high-intensity physical activity, such as symptomatic valvular heart disease, hypertrophic cardiomyopathy, uncontrolled hypertension, in-compensated heart failure, serious arrythmia not under control after treatment, pulmonary hypertension, significant angina after revascularization and optimal drug treatment.
Show all 11Show fewer
- Renal insufficiency requiring dialysis.
- Any end-stage somatic disease with short life expectancy or that is expected to interfere with the participants' ability to comply with the study protocol, such as advanced cancer, chronic lung disease with exacerbations, or other disease, as determined by study personnel.
- Inability to comply with the study protocol due to any physical disability, somatic disease or mental problem, as determined by study personnel.
- Residing in nursing home or other institution.
- Participation in another trial with exercise as an intervention modality.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Norwegian Trial of Physical Exercise After Myocardial Infarction. A Nationwide Randomized Clinical Trial After Myocardial Infarction to Determine the Effects of Supervised Physical Activity on Long-term Mortality and Morbidity
Myocardial infarction (MI) remains the main cause of death in Europe with about 2 million deaths annually. According to WHO, 30 % of deaths caused by MI could be prevented if the populations adhere to official guidelines for physical activity. However, secondary prevention trials in MI patients have been of insufficient size or quality to provide conclusive evidence that physical activity reduces the risk of death or recurrent cardiovascular diseases. NorEx is the first study able to provide such evidence.
NorEx is a registry-based prospective, three-arm, randomized multicenter secondary prevention clinical trial with blinded end-point evaluation (PROBE design). The aim of the study is to investigate whether, and to what extent, moderate to high intensity supervised physical activity will reduce the risk of recurrent cardiovascular disease and death among people who have suffered a myocardial infarction. The intervention group consists of Approximately 3185 participants who will be trained to exercise for 4 years under supervision of a personal trainer. The study design includes two control groups each consisting of approximately 3200 patients.The primary composite endpoint is time to all-cause death, nonfatal acute myocardial infarction or nonfatal stroke, whatever comes first during 4 years of follow-up. The study is powered to detect a 20 % difference in the incidence of the primary endpoint between the intervention group and the control groups. Novel health IT technology was specifically designed for NorEx, including a smart watch, a NorEx mobile application and a manager portal which allows the trainers to interact with the participants. Follow-up of the participants will be through national health registries for up to 10 years after study completion.
- Conditions
- Myocardial Infarction
- Being tested
- Physical exercise, Standard care, Observation group
- Keywords
- Exercise therapy, Secondary prevention
- Medical subject headings
- Myocardial Infarction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Physical exerciseBehavioural
Supervised home-based and community-based physical exercise with a dose required to increase cardiorespiratory fitness, i.e. intensity, duration and frequency that accumulates to at least 115 minutes a week of exercise, divided into at least 20 minutes a week of high/vigorous intensity physical activity (active minutes at about 85% of peak heart rate or Rated Perceived Exertion [RPE] of about 16 on Borg scale) and 95 minutes a week at moderate-intensity physical activity (active minutes at about 70% of peak heart rate or RPE of about 13 on Borg Scale), or continuous heart rate measurements amounting to at least 100 Personal Activity Intelligence (PAI) equivalents per week.
Standard careBehavioural
Standard care, i.e. advice at study start to follow international guidelines of moderate to vigorous physical activity intensity without further guidance and follow-up by study personnel.
Observation groupBehavioural
Follow-up through mandatory national heath registries for primary endpoint, without any contact by study personnel
| Study group | Role | What they receive |
|---|---|---|
| Physical exercise | Experimental | Supervised home-based and community-based physical exercise with a dose required to increase cardiorespiratory fitness, i.e. intensity, duration and frequency that accumulates to at least 115 minutes a week of exercise, divided into at least 20 minutes a week of high/vigorous intensity physical activity (active minutes at about 85% of peak heart rate or Rated Perceived Exertion [RPE] of about 16 on Borg scale) and 95 minutes a week at moderate-intensity physical activity (active minutes at about 70% of peak heart rate or RPE of about 13 on Borg Scale), or continuous heart rate measurements amounting to at least 100 Personal Activity Intelligence (PAI) equivalents per week. Receives: Behavioral: Physical exercise |
| Control group I | Active comparator | Standard care, i.e. advice at study start to follow international guidelines of moderate to vigorous physical activity intensity without further guidance and follow-up by study personnel. Receives: Behavioral: Standard care |
| Control group II (observation group) | Other | Follow-up through mandatory national heath registries for primary endpoint, without any contact by study personnel. Receives: Behavioral: Observation group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to all-cause mortality, or nonfatal myocardial infarction, or nonfatal stroke, whichever comes first.
Mortality will be assessed by linkage to the Norwegian Cause of Death Register with the use of a unique 11-digit Norwegian national identification number for each patient. The Cause of Death Register is completed by law for all deaths. Nonfatal myocardial infarction and nonfatal stroke are assessed by linkage to The Norwegian Myocardial Infarction Register and the Norwegian Stroke Register, with the use of a unique 11-digit Norwegian national identification number for each patient. All Norwegian hospitals are required by law to complete these registers for hospitalized patients.
Measured: 4 years
Secondary outcomes (12)
Time to all-cause mortality, or nonfatal myocardial infarction, or nonfatal stroke, whichever comes first.
Mortality will be assessed by linkage to the Norwegian Cause of Death Register with the use of a unique 11-digit Norwegian national identification number for each patient. The Cause of Death Register is completed by law for all deaths. Nonfatal myocardial infarction and nonfatal stroke are assessed by linkage to The Norwegian Myocardial Infarction Register and the Norwegian Stroke Register, with the use of a unique 11-digit Norwegian national identification number for each patient. All Norwegian hospitals are required by law to complete these registers for hospitalized patients.
Measured: 10 years
Time to all-cause mortality, cardiac death, vascular death, noncardiovascular death, death from cancer.
Mortality will be assessed by linkage to the Norwegian Cause of Death Register with the use of a unique 11-digit Norwegian national identification number for each patient. The Cause of Death Register is completed by law for all deaths.
Measured: 4 years and 10 years
Time to hospitalization with a diagnosis of nonfatal myocardial infarction, stroke, unstable angina pectoris, atrial fibrillation, or psychiatric disease, or a coronary revascularization procedure, or any hospitalization.
Information about hospitalizations and the discharge diagnoses will be collected by means of electronic linkage to the Norwegian Patient Registry with the use of a unique 11-digit Norwegian national identification number for each patient. The Norwegian National Patient Registry includes the codes of the International Classification of Diseases, 10th Revision (ICD-10), with respect to all the main diagnoses and up to 20 secondary diagnoses and all the procedure codes from all hospitalizations in Norway.
Measured: 4 years and 10 years
Change in health related quality of life
HeartQoL questionnaire is a core ischemic heart disease specific health related quality of life questionnaire (HRQL). The questionnaire comprises 14-items with 10-item physical and 4-item emotional subscales which are scored from 0 (poor HRQL) to 3 (better HRQL) with a global score if need.
Measured: Study start, 4 years and 10 years
Change in anxiety and depression
The Hospital Anxiety and Depression Scale (HADS) measure symptoms of anxiety and depression. The HADS is a 14 item scale where seven of the items relate to anxiety and seven relate to depression.The respondent rates each item on a 4-point scale from 0 (absence) to 3 (extreme presence). The total score is 42 (21 per subscale).
Measured: Study start, 4 and 10 years
Physical and mental dimensions of health
RAND-12 measures physical and mental dimensions of health. The 12 items in the questionnaire correspond to eight principal physical and mental health domains. The 12 items are summarized into two scores, a "Physical Health Summary Measure (PCS-physical component score)" and a "Mental Health Summary Measure (MCS-mental component score).
.
Measured: Study start, 4 years and 10 years
Changes in insomnia
The Bergen Insomnia Scale measure sleeping pattern and insomnia. The 6 items in the questionnaire are scored from 0 (absence) to 7 (every night) and are summarized to a total score with a max value between 0 (no insomnia) to 42 (extreme insomnia).
Measured: Study start, 4 years and 10 years
The number of consultations with a primary health care physician during the study
The number of consultations in primary health care will be collected by linkage to the Norwegian KUHR database with the use of a unique 11-digit Norwegian national identification number for each patient.
Measured: 4 and 10 years
Use of prescription drugs
Use of prescription drugs during the study will be collected by linkage to the Norwegian Drug Prescription Database with the use of a unique 11-digit Norwegian national identification number for each patient.
Measured: 4 and 10 years
Change in memory
The following 8 questions about memory will be administered by a self-administered questionnaire at start of the study and after 3.5 year and 10 years:
- Do you have problems with the memory?
- Are these problems worse than among other people on your age?
- Do have problems with remembering other persons name?
- Do have problems with following a conversation?
- Do have problems with remembering what happened a few minutes ago?
- Do have problems with doing what you have planned to do? 7 Do have problems with remembering dates?
- Do have problems with remembering events that took place a few days ago? The response categories for all questions are: "Never (0)", "Little or sometimes (1)", or "Often (2)".
The scores for question 3 to 8 may be summarized to a total score between 0 (No memory problems) and 18 (severe memory problems).
Measured: 4 and 10 years
Change in peak oxygen uptake (VO2peak) (mL/kg/min)
Peak oxygen uptake will be measured with standard equipment for indirect calorimetry in an incremental protocol until exhaustion on either a treadmill or a bicycle ergometer. Measurements will be performed each year during the study in random samples of 150 participants in the experimental physical exercise arm and 150 participants in the active comparator arm (control group I)
Measured: Study start, 1 year, 4 years
Physical activity
A self-administered questionnaire with questions about frequency of weekly physical activity, intensity level, and amount of weekly physical activity will be administered at baseline and end of study (3.5 years). The questionnaire consist of the following 6 questions:
How many times do you exercise per week? (4 response categories). If you exercise 1 time or more per week, at what intensity level do you usually exercise (3 response categories).
How many minutes do you usually exercise each time (4 response categories) How many hours per day do you spend in a sitting position ( number of hours) Do you participate in endurance sport competitions? (no, yes)
Measured: Study start, 4 years, 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Nov 2020
- Study start29 Sep 2020
- Primary completion19 May 2025
- Study completion31 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Myocardial InfarctionStudies of the same condition, open and under way.
- More trials run by Norwegian University of Science and TechnologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Prospective randomized controlled trial with blinded endpoint evaluation
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 9,513 participants (actual)
Sponsor and investigators
- Lead sponsor
- Norwegian University of Science and Technology
- Sponsor type
- University, hospital or other
- Collaborators
- Universitetssykehuset i Nord-Norge Hospital Trust, Helse-Bergen HF, Helse Sorlandet Hospital Trust, Finnmark Hospital Trust, Helgelandssykehuset Hospital Trust, Nordlandssykehuset Hospital Trust, Helse Fonna Hospital Trust, Helse Forde Hospital Trust, Helse Møre og Romsdal Hospital Trust, Helse Nord-Trøndelag HF, Akershus University Hospital Trust, Diakonhjemmet Hospital, Sykehuset Innlandet Hospital Trust, Sykehuset Telemark Hospital Trust, Sykehuset i Vestfold Hospital Trust, Helse Stavanger Hospital Trust, Vestre Viken Hospital Trust, Helse Midt-Norge Hospital Trust, University of Oslo, University of Bergen, University of Tromso, Haraldsplass Hospital AS, Lovisenberg Hospital AS, Sykehuset Ostvold Hospital Trust, St. Olavs Hospital, Oslo University Hospital
- Responsible party
- Sponsor
- Investigators
- Øystein Risa, Study director, Norwegian University of Science and TechnologyKaare Bønaa, MD prof, Principal investigator, Norwegian University of Science and Technology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04617639
- Sponsor's protocol ID
- 12128
- Other IDs
- 287618, 287380
- Acronym
- NorEx
- Status last verified
- Oct 2026
- First submitted
- 21 Oct 2020
- Last updated
- 19 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: To be decided
Publications
Svenningsen A, Soderstrom S, Bucher Sandbakk S, Gullestad L, Bonaa KH, Wisloff U, Hollekim-Strand SM. Mind the intention-behavior gap: a qualitative study of post-myocardial infarction patients' beliefs and experiences with long-term supervised and self-monitored physical exercise. BMC Sports Sci Med Rehabil. 2024 Sep 27;16(1):204. doi: 10.1186/s13102-024-00987-2.
PubMed 39334432
Study at a glance
From the registry record, last updated by the sponsor on 19 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Norwegian Trial of Physical Exercise After Myocardial Infarction. A Nationwide Randomized Clinical Trial After Myocardial Infarction to Determine the Effects of Supervised Physical Activity on Long-term Mortality and Morbidity
- ClinicalTrials.gov ID
- NCT04617639
- Acronym / sponsor ID
- NorEx / 12128
- Conditions
- Myocardial Infarction
- Keywords
- Exercise therapy, Secondary prevention
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 9,513 participants (actual)
- Lead sponsor
- Norwegian University of Science and TechnologyUniversity, hospital or other
- Collaborators
- Universitetssykehuset i Nord-Norge Hospital Trust, Helse-Bergen HF, Helse Sorlandet Hospital Trust, Finnmark Hospital Trust, Helgelandssykehuset Hospital Trust, Nordlandssykehuset Hospital Trust, Helse Fonna Hospital Trust, Helse Forde Hospital Trust, Helse Møre og Romsdal Hospital Trust, Helse Nord-Trøndelag HF, Akershus University Hospital Trust, Diakonhjemmet Hospital, Sykehuset Innlandet Hospital Trust, Sykehuset Telemark Hospital Trust, Sykehuset i Vestfold Hospital Trust, Helse Stavanger Hospital Trust, Vestre Viken Hospital Trust, Helse Midt-Norge Hospital Trust, University of Oslo, University of Bergen, University of Tromso, Haraldsplass Hospital AS, Lovisenberg Hospital AS, Sykehuset Ostvold Hospital Trust, St. Olavs Hospital, Oslo University Hospital
- Study start
- 29 Sep 2020 (actual)
- Primary completion
- 19 May 2025 (actual)
- Study completion
- 31 Dec 2028 (estimated)
- First posted
- 5 Nov 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Myocardial infarction (MI) remains the main cause of death in Europe with about 2 million deaths annually. According to WHO, 30 % of deaths caused by MI could be prevented if the populations adhere to official guidelines for physical activity. However, secondary prevention trials in MI patients have been of insufficient size or quality to provide conclusive evidence that physical activity reduces the risk of death or recurrent cardiovascular diseases. NorEx is the first study able to provide such evidence.
NorEx is a registry-based prospective, three-arm, randomized multicenter secondary prevention clinical trial with blinded end-point evaluation (PROBE design). The aim of the study is to investigate whether, and to what extent, moderate to high intensity supervised physical activity will reduce the risk of recurrent cardiovascular disease and death among people who have suffered a myocardial infarction. The intervention group consists of Approximately 3185 participants who will be trained to exercise for 4 years under supervision of a personal trainer. The study design includes two control groups each consisting of approximately 3200 patients.The primary composite endpoint is time to all-cause death, nonfatal acute myocardial infarction or nonfatal stroke, whatever comes first during 4 years of follow-up. The study is powered to detect a 20 % difference in the incidence of the primary endpoint between the intervention group and the control groups. Novel health IT technology was specifically designed for NorEx, including a smart watch, a NorEx mobile application and a manager portal which allows the trainers to interact with the participants. Follow-up of the participants will be through national health registries for up to 10 years after study completion.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 3
- Model description
- Prospective randomized controlled trial with blinded endpoint evaluation
| Arm | Type | Receives |
|---|---|---|
| Physical exercise | Experimental | Behavioral: Physical exerciseSupervised home-based and community-based physical exercise with a dose required to increase cardiorespiratory fitness, i.e. intensity, duration and frequency that accumulates to at least 115 minutes a week of exercise, divided into at least 20 minutes a week of high/vigorous intensity physical activity (active minutes at about 85% of peak heart rate or Rated Perceived Exertion [RPE] of about 16 on Borg scale) and 95 minutes a week at moderate-intensity physical activity (active minutes at about 70% of peak heart rate or RPE of about 13 on Borg Scale), or continuous heart rate measurements amounting to at least 100 Personal Activity Intelligence (PAI) equivalents per week. |
| Control group I | Active comparator | Behavioral: Standard careStandard care, i.e. advice at study start to follow international guidelines of moderate to vigorous physical activity intensity without further guidance and follow-up by study personnel. |
| Control group II (observation group) | Other | Behavioral: Observation groupFollow-up through mandatory national heath registries for primary endpoint, without any contact by study personnel. |
Who may qualify
- Ages
- 18 to 79 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Hospitalized in a Norwegian hospital with an acute myocardial infarction (Type I) during 2013-2022. Patients are included minimum 3 months after hospitalization when they are in a stable clinical condition.
- Norwegian national identification number
- Able to communicate in Norwegian or other Scandinavian language
- Being able to be physically active according to study protocol, as determined by study personnel.
- Signed informed consent.
Key exclusion criteria (11 listed)
- Persons who already participate in physical activity at a similar or higher level than what is prescribed for the intervention group, as determined by study personnel.
- Participating or plans to participate in endurance sport competitions.
- Expected to emigrate during the study
- Cognitive impairment/dementia.
- Alcohol or drug abuse, or serious psychiatric disease.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Physical exerciseSupervised home-based and community-based physical exercise with a dose required to increase cardiorespiratory fitness, i.e. intensity, duration and frequency that accumulates to at least 115 minutes a week of exercise, divided into at least 20 minutes a week of high/vigorous intensity physical activity (active minutes at about 85% of peak heart rate or Rated Perceived Exertion [RPE] of about 16 on Borg scale) and 95 minutes a week at moderate-intensity physical activity (active minutes at about 70% of peak heart rate or RPE of about 13 on Borg Scale), or continuous heart rate measurements amounting to at least 100 Personal Activity Intelligence (PAI) equivalents per week. | Behavioural | Physical exercise |
| Standard careStandard care, i.e. advice at study start to follow international guidelines of moderate to vigorous physical activity intensity without further guidance and follow-up by study personnel. | Behavioural | Control group I |
| Observation groupFollow-up through mandatory national heath registries for primary endpoint, without any contact by study personnel | Behavioural | Control group II (observation group) |
Primary outcome
Time to all-cause mortality, or nonfatal myocardial infarction, or nonfatal stroke, whichever comes first.
Time frame: 4 years
Mortality will be assessed by linkage to the Norwegian Cause of Death Register with the use of a unique 11-digit Norwegian national identification number for each patient. The Cause of Death Register is completed by law for all deaths. Nonfatal myocardial infarction and nonfatal stroke are assessed by linkage to The Norwegian Myocardial Infarction Register and the Norwegian Stroke Register, with the use of a unique 11-digit Norwegian national identification number for each patient. All Norwegian hospitals are required by law to complete these registers for hospitalized patients.
12 secondary outcomes
Time to all-cause mortality, or nonfatal myocardial infarction, or nonfatal stroke, whichever comes first.
Time frame: 10 years
Time to all-cause mortality, cardiac death, vascular death, noncardiovascular death, death from cancer.
Time frame: 4 years and 10 years
Time to hospitalization with a diagnosis of nonfatal myocardial infarction, stroke, unstable angina pectoris, atrial fibrillation, or psychiatric disease, or a coronary revascularization procedure, or any hospitalization.
Time frame: 4 years and 10 years
Change in health related quality of life
Time frame: Study start, 4 years and 10 years
Change in anxiety and depression
Time frame: Study start, 4 and 10 years
Physical and mental dimensions of health
Time frame: Study start, 4 years and 10 years
Changes in insomnia
Time frame: Study start, 4 years and 10 years
The number of consultations with a primary health care physician during the study
Time frame: 4 and 10 years
Use of prescription drugs
Time frame: 4 and 10 years
Change in memory
Time frame: 4 and 10 years
Change in peak oxygen uptake (VO2peak) (mL/kg/min)
Time frame: Study start, 1 year, 4 years
Physical activity
Time frame: Study start, 4 years, 10 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Oct 2026.
- Derived from this study: PubMed 39334432Svenningsen A, Soderstrom S, Bucher Sandbakk S, Gullestad L, Bonaa KH, Wisloff U, Hollekim-Strand SM. Mind the intention-behavior gap: a qualitative study of post-myocardial infarction patients' beliefs and experiences with long-term supervised and self-monitored physical exercise. BMC Sports Sci Med Rehabil. 2024 Sep 27;16(1):204. doi: 10.1186/s13102-024-00987-2.
- Individual participant dataSharing planned: Yes. To be decided
Related trials for Myocardial Infarction
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
Active, not recruitingObservational study
A Longitudinal Cohort Study to Evaluate Cardiovascular Risk Factors and Disease in Haiti
Hypertension, Diabetes
Active, not recruitingPhase 3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Primary Prevention of Atherosclerotic Cardiovascular Disease
Enrolling by invitation
The DANE-HEART Trial - Computed Tomography Coronary Angiography for Primary Prevention
Coronary Atherosclerosis and Other Heart Disease, Cardiovascular Diseases
Not yet recruitingObservational study
Elicit Drugs in Myocardial Infarction
Young Patients With Acute Myocardial Infarction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Øystein Risa study director
Norwegian University of Science and Technology
Kaare Bønaa, MD prof principal investigator
Norwegian University of Science and Technology
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Physical exercise and Observation group in people with Myocardial Infarction, run by Norwegian University of Science and Technology at 1 site in Norway.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 19 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to all-cause mortality, or nonfatal myocardial infarction, or nonfatal stroke, whichever comes first. (time frame: 4 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04617639, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Oct 2026.